Clinical trials: Hepatobiliary Disorders
Hypercholesterolemia
Pravastatin Efficacy and Safety Trial in Hypercholesterolemic Patients With Chronic Liver Disease
To determine in hypercholesterolemic subjects with chronic, well-compensated liver disease, the percent change from baseline to Week 12 in serum LDL-C of pravastatin 80 mg compared to placebo.
- Trial name
- NCT00529178
- Testing
- Pravastatin
- Volunteers
- 232 people
- Sponsor
- Bristol-Myers Squibb
NASH - Nonalcoholic Steatohepatitis
A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (Symmetry)
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in cirrhotic subjects with biopsy-proven F4 compensated NASH.
- Trial name
- NCT05039450
- Testing
- EFX
- Where
- 49 sites in United States, Mexico and 1 more
- Volunteers
- 213 people
- Sponsor
- Akero Therapeutics, Inc
Nonalcoholic Steatohepatitis
Norursodeoxycholic Acid vs. Placebo in NASH
This is a double-blind, randomised, multi-centre, placebo-controlled, comparative, phase IIb trial. The trial will be conducted with three treatment groups in the form of a parallel group comparison and will serve to compare oral…
- Trial name
- NCT05083390
- Testing
- norUrsodeoxycholic acid
- Where
- Austria
- Volunteers
- 363 people
- Sponsor
- Dr. Falk Pharma GmbH
Hepatobiliary and Pancreatic Diseases
Remote Versus On-Site Robotic Surgery for Hepatobiliary and Pancreatic Procedures
This study will compare remote robotic surgery with on-site robotic surgery for patients who need surgery for diseases of the liver, bile duct, gallbladder, or pancreas.
- Trial name
- NCT07716423
- Testing
- Remote Robotic Surgery, On-Site Robotic Surgery
- Volunteers
- 168 people
- Sponsor
- West China Hospital
NASH - Nonalcoholic Steatohepatitis
A Drug-drug Interaction Study to Investigate the Effect of Coadministration of EDP-305 on the PK of a Combined Oral Contraceptive in Healthy Female Subjects
A Phase 1, Open-label, Fixed-sequence Study to Investigate the Effects of EDP 305 on the Pharmacokinetics of a Combined Oral Contraceptive in Healthy Adult Female Subjects
- Trial name
- NCT03783897
- Testing
- EDP-305, Oral Contraceptive
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Enanta Pharmaceuticals, Inc
NAFLD
NAFLD in Diabetes Type 2 in Primary Care
The EPSONIP (Evaluating Prevalence and Severity Of NAFLD In Primary care) trial is a longitudinal cohort study of patients with T2DM recruited from primary health care centers in Östergötland, Sweden.
- Trial name
- EPSONIP (NCT03864510)
- Where
- 2 sites in Sweden
- Volunteers
- 317 people
- Sponsor
- Linkoeping University
End Stage Liver Disease
Functional Assessment in Liver Transplantation
This will be a prospective cohort study of patients with liver disease. Subjects will undergo geriatric assessments of frailty, functional status, and disability using functional status measures at baseline and at every clinic…
- Trial name
- FrAILT (NCT03228290)
- Where
- 12 sites in United States
- Volunteers
- 5,000 people
- Sponsor
- University of California, San Francisco
Non-Alcoholic Steato-Hepatitis, Liver Cirrhosis
Genetic Studies of Non-Alcoholic Fatty Liver Disease
Background: Non-alcoholic fatty liver disease is the most common form of liver disease in the United States. It includes many conditions.
- Conditions
- Non-Alcoholic Steato-Hepatitis, Liver Cirrhosis, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT01629095
- Where
- 5 sites in United States
- Volunteers
- 17 people
- Sponsor
- National Human Genome Research Institute (NHGRI)
Type 2 Diabetes, Nonalcoholic Steatohepatitis
Sitagliptin for the Treatment of Non-alcoholic Steatohepatitis in Patients With Type 2 Diabetes
This is a randomized, double-blind, placebo-controlled trial evaluating the impact of sitagliptin therapy in patients with concomitant type 2 diabetes and non-alcoholic steatohepatitis (NASH) on improving liver disease based on…
- Trial name
- NCT01260246
- Testing
- sitagliptin
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Fatty Liver, Liver Fibrosis
Effects of Docosahexaenoic Acid (DHA) on Children With Nonalcoholic Fatty Liver Disease (NAFLD)
The purpose of this interventional study is to evaluate the efficacy and tolerability of docosahexaenoic acid (DHA) in children or adolescents with well-characterized and liver biopsy confirmed nonalcoholic fatty liver disease…
- Conditions
- Fatty Liver, Liver Fibrosis, Obesity, Metabolic Syndrome
- Trial name
- EDACN (NCT00885313)
- Testing
- DHA250, DHA500, Lifestyle intervention
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Bambino Gesù Hospital and Research Institute
Parenteral Nutrition Associated Liver Disease
Parenteral Nutrition Associated Liver Disease: Early Markers and Therapy Wih Enteral Omega-3 Supplementation
Cholestatic liver disease is a common complication associated with long term parenteral nutrition (PN). PN associated liver disease (PNALD) is much more common in premature infants and the incidence increases with duration of PN.
- Trial name
- NCT01157780
- Testing
- Lovaza (fish oil)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Tennessee
Hepatic Steatosis
A Clinical Trial of Longqi Jiangzhi Decoction Against Non-alcoholic Fatty Liver Disease
The goal of this clinical trial is to learn if Longqi Jiangzhi decoction works to treat non-alcoholic fatty liver disease in adults. It will also learn about the safety of drug Longqi Jiangzhi decoction.
- Trial name
- NCT07320456
- Testing
- Longqi Jiangzhi decoction
- Volunteers
- 80 people
- Sponsor
- Shanghai Municipal Hospital of Traditional Chinese Medicine
Cholestasis in Newborn, Biliary Atresia
The Dirty Nappy Study
This observational study evaluates whether a machine-learning algorithm, a computer program that learns patterns from data, can accurately diagnose cholestasis in newborns.
- Conditions
- Cholestasis in Newborn, Biliary Atresia, Neonatal Cholestasis
- Trial name
- NCT07697872
- Where
- United Kingdom
- Volunteers
- 5,350 people, healthy volunteers welcome
- Sponsor
- Birmingham Women's and Children's NHS Foundation Trust
Portal Hypertension, Hepatic Decompensation
Non-selective Beta-blocker in Compensated Advanced Chronic Liver Disease
The goal of this randomised controlled trial is to evaluate the effect of carvedilol (a non-selective beta-blocker) in patients with compensated advanced chronic liver disease under clinically significant portal hypertension or…
- Conditions
- Portal Hypertension, Hepatic Decompensation, Advanced Chronic Liver Disease
- Trial name
- BB_cACLD (NCT06449339)
- Testing
- Carvedilol
- Where
- Hong Kong
- Volunteers
- 474 people
- Sponsor
- Chinese University of Hong Kong
Fatty Liver
Limonene on Regulating Metabolism-related Fatty Liver Disease (MAFLD) and Analysis of TCM Constitution
The prevention and treatment of metabolic-related fatty liver disease (MAFLD) involves many fields in preventive medicine and clinical medicine.
- Trial name
- DL-MAFLD-TCM (NCT04853082)
- Testing
- Limonene capsule
- Where
- China
- Volunteers
- 57 people
- Sponsor
- Hongsheng Tan
Hepatitis C, Hepatitis B
Noninvasive Staging of Liver Fibrosis: MR vs Ultrasound
Liver fibrosis is an important public health problem, with a substantial morbidity and mortality due to progression to cirrhosis and hepatocellular carcinoma. All causes of chronic liver disease may lead to fibrosis.
- Conditions
- Hepatitis C, Hepatitis B, Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH)
- Trial name
- ELF (NCT02044523)
- Testing
- Transient elastography, acoustic radiation force impulse, magnetic resonance elastography
- Where
- Canada
- Volunteers
- 108 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Compensated Advanced Chronic Liver Disease
Impact of Metabolic Disorders on cACLD Outcomes
This multicenter, prospective, cohort study is designed to investigate how metabolic disorders (such as obesity, diabetes, and high cholesterol) influence the progression of liver disease in patients with compensated advanced…
- Trial name
- NCT07534046
- Testing
- Observational Study
- Volunteers
- 4,307 people
- Sponsor
- The Second Affiliated Hospital of Chongqing Medical University
Liver Diseases, Hepatic Insufficiency
A Pharmacokinetic Study of Baricitinib in Participants With Liver Disease
The main purpose of this study is to measure how much of the study drug called baricitinib gets into the blood stream and how long it takes the body to get rid of it. Healthy participants and those with liver disease may enroll.
- Trial name
- NCT01870388
- Testing
- Baricitinib
- Where
- 2 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Cirrhosis, Sepsis
Cohort Study of Chronic Liver Disease Complicated by Sepsis
Study population: Patients with liver cirrhosis complicated by sepsis Observation indicators: Fluid resuscitation strategy, early dynamic indicators such as MAP Observation endpoint: 28-day all-cause mortality Study design…
- Trial name
- NCT07465003
- Volunteers
- 1,600 people, healthy volunteers welcome
- Sponsor
- The Second Affiliated Hospital of Chongqing Medical University
NAFLD
Comparison of Two sTRAtegies For the Non-Invasive Diagnosis of advanCed Liver Fibrosis in NAFLD
NAFLD, closely linked to overweight and insulin resistance, has reached 25% prevalence worldwide. Advanced liver fibrosis(ALF) must be accurately diagnosed in NAFLD because it defines a subgroup of patients with impaired…
- Trial name
- TRAFIC (NCT04681573)
- Testing
- blood tests
- Where
- 20 sites in France
- Volunteers
- 1,045 people
- Sponsor
- University Hospital, Angers
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.